KEGG DRUG: Patritumab
WEBPatritumab (USAN/INN) Formula: C6542H10072N1740O2038S40. Exact mass: 146896.6813. Mol weight: 146987.07. Sequence (Heavy chain) QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQP PGKGLEWIGE INHSGSTNYN PSLKSRVTIS VETSKNQFSL KLSSVTAADT AVYYCARDKW TWYFDLWGRG TLVTVSSAST
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth …
WEBOct 6, 2023 · Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conjugate that is being evaluated as a novel treatment in HER3-expressing advanced breast cancer in the U31402-A-J101 study.
Patritumab deruxtecan (HER3-DXd), a novel HER3 directed …
WEBPatritumab deruxtecan (HER3-DXd, U3-1402) is a novel, investigational HER3 directed ADC that includes 3 key components: a fully human anti-HER3 immunoglobulin G1 (IgG1) mAb (patritumab), covalently linked to a topoisomerase I inhibitor payload (an exatecan derivative) via a tetrapeptide-based cleavable linker .
AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, …
WEBSep 9, 2023 · Using patritumab, T moiety–exatecan antibody conjugate P-T moiety-exatecan displayed improved antitumor efficacy compared with P-GGFG-DXd, especially in low HER3 and high MDR expression tumors . Here we have employed a more holistic approach in designing and characterizing a novel HER3-targeting ADC, AMT-562, for clinical investigation.
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan …
WEBSep 10, 2023 · Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker.
Results from the phase 1/2 study of patritumab deruxtecan, a …
WEBJun 2, 2022 · Background: Patritumab deruxtecan (HER3-DXd) is a novel, investigational ADC composed of a human anti-HER3 monoclonal antibody covalently bound to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker.
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth …
WEBDec 20, 2023 · Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conjugate that is being evaluated as a novel treatment in HER3-expressing advanced breast cancer in the U31402-A-J101 study. Methods: Adults with disease progression on previous therapies were eligible.
Patritumab Deruxtecan Demonstrated Clinically Meaningful and …
WEBSep 10, 2023 · Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo’s (TSE: 4568) proprietary DXd ADC technology.
Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR …
WEB5 days ago · Patritumab deruxtecan granted priority review in the U.S. for certain patients with previously treated locally advanced or metastatic EGFR-mutated non-small cell lung cancer. News release. Merck.
Patritumab Deruxtecan Demonstrates a Manageable Safety …
WEBOct 19, 2023 · In HER3-expressing xenograft models, patritumab deruxtecan demonstrated antitumour responses across a range of baseline HER3 expression levels that were sustained over time. In vitro studies have shown that patritumab deruxtecan inhibits the proliferation of chemotherapy-resistant breast cancer cell lines with upregulated baseline HER3 expression.